Abstract
Jote BulchaUniversity of Massachusetts Medical School“The current AAV-based viral vector production methods cannot meet demand for conducting large-scale clinical trials and commercial applications. Therefore, there is an urgent need to develop innovative AAV production schemes to turn the promise of gene therapy treatments into a reality.”
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
